March 28, 2017 / 1:11 PM / 4 months ago

BRIEF-Indivior announces additional RBP-6000 clinical study results

1 Min Read

March 28 (Reuters) - Indivior Plc:

* Additional RBP-6000 clinical study results

* Additional subanalysis results from phase 2 and phase 3 studies that combined more than 17,000 observations from 507 subjects

* Findings support that RBP-6000 across 1-month period can suppress withdrawal symptoms and craving, block subjective effects of opioid agonists Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below